The principal interest of our group is to improve technology, strategies, and micro-methods for polypeptide isolation, mass spectrometric protein identification, and mapping of modified amino acids. The program draws from conventional biochemistry as well as from the fields of chemistry and engineering. These novel tools have found widespread use in the health and life sciences as a resource for the larger research community, and for our own studies on gene expression, proteomics of the human transcriptional machinery, protein modification profiling, and serum peptide diagnostics.
Paul Tempst, PhD
Research FocusMolecular biologist Paul Tempst focuses on the development of proteomic technologies and approaches for studying the eukaryotic transcriptional machineries and for cancer biomarker discovery.
EducationPhD, Universiteit Gent
- Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, Villanueva J, Saghatelian A, Assel M, Vickers AJ, Eastham JA, Scher HI, Carver BS, Lilja H, Tempst P. Inhibition of circulating DPP4 activity in patients with metastatic prostate cancer. Mol Cell Proteomics 2014; 13:3082-3096. PMCID: PMC4223493
- Taylor JM, Yaneva M, Velasco K, Philip J, Erdjument-Bromage H, Ostrovnaya I, Lilja HG, Bochner BH, Tempst P. Aminopeptidase activities as prospective urinary biomarkers for bladder cancer. Proteomics Clinical Applic 2014; 8:317-326. PMCID: PMC4059539
- Executive Committee Member, National Cancer Institute’s Clinical Proteomic Technologies Assessment for Cancer initiative (2006-2011)
- Council Member, US Human Proteome Organization (2004-2012)
- Discovery and molecular identification/characterization of the following: NFkappaB; IkappaB; NF-E2; PI3K; mTOR; Raptor; p27kip; SNAREs; histone-deacetylases, -methylases, and -demethylases; and the Mediator, Elongator, Polycomb, RSC, Swi/Snf, Compass, and Exosome complexes
- Use of protease activities as biomarkers for cancer